AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.72-2.61 (-2.41%) ▼|ACN178.68-8.05 (-4.31%) ▼|ADBE257.90-8.61 (-3.23%) ▼|AMAT470.10+15.39 (+3.38%) ▲|AMD508.05+30.48 (+6.38%) ▲|AMGN395.81-41.42 (-9.47%) ▼|AMT177.45+1.60 (+0.91%) ▲|AMZN257.21-1.30 (-0.50%) ▼|AVGO371.22+13.32 (+3.72%) ▲|AXP327.57+1.41 (+0.43%) ▲|BA215.19+2.94 (+1.39%) ▲|BAC62.65-0.04 (-0.06%) ▼|BKNG182.48-10.81 (-5.59%) ▼|BLK1,106.10-10.46 (-0.94%) ▼|BMY65.01-1.81 (-2.71%) ▼|BNY164.30-0.55 (-0.33%) ▼|BRK-B504.34-1.69 (-0.33%) ▼|C137.64-0.09 (-0.06%) ▼|CAT828.40+14.46 (+1.78%) ▲|CL88.20-0.57 (-0.64%) ▼|CMCSA26.15-0.35 (-1.30%) ▼|COF216.29-3.32 (-1.51%) ▼|COP135.48+1.22 (+0.91%) ▲|COST907.74-8.01 (-0.87%) ▼|CRM250.47-8.77 (-3.38%) ▼|CSCO109.38+0.18 (+0.16%) ▲|CVS95.76-0.98 (-1.02%) ▼|CVX211.10+2.50 (+1.20%) ▲|DE683.73-9.80 (-1.41%) ▼|DHR205.78-1.88 (-0.91%) ▼|DIS104.56-0.75 (-0.71%) ▼|DUK121.17+0.95 (+0.79%) ▲|EMR153.67+0.85 (+0.56%) ▲|FDX318.85-3.67 (-1.14%) ▼|GD356.23-3.17 (-0.88%) ▼|GE338.87+1.75 (+0.52%) ▲|GEV961.23+19.28 (+2.05%) ▲|GILD146.16-4.84 (-3.20%) ▼|GM85.74-2.02 (-2.30%) ▼|GOOG335.45+0.14 (+0.04%) ▲|GOOGL338.53+0.07 (+0.02%) ▲|GS1,039.75+1.14 (+0.11%) ▲|HD317.30-3.75 (-1.17%) ▼|HON208.59-1.02 (-0.49%) ▼|IBM232.56-2.33 (-0.99%) ▼|INTC104.17+8.37 (+8.74%) ▲|INTU314.87-17.83 (-5.36%) ▼|ISRG350.35-16.35 (-4.46%) ▼|JNJ267.95-7.28 (-2.65%) ▼|JPM356.50-2.15 (-0.60%) ▼|KO87.91-0.16 (-0.18%) ▼|LIN470.26-7.31 (-1.53%) ▼|LLY1,119.32-30.04 (-2.61%) ▼|LMT540.95+15.67 (+2.98%) ▲|LOW202.44-2.02 (-0.99%) ▼|LRCX321.09+13.44 (+4.37%) ▲|MA568.31-10.91 (-1.88%) ▼|MCD255.65-0.04 (-0.02%) ▼|MDLZ60.97-0.31 (-0.51%) ▼|MDT91.82-2.35 (-2.50%) ▼|META616.72-0.05 (-0.01%) ▼|MMM166.26-2.30 (-1.36%) ▼|MO67.93-0.95 (-1.38%) ▼|MRK148.31-2.02 (-1.34%) ▼|MS218.05+0.33 (+0.15%) ▲|MSFT492.98-6.72 (-1.34%) ▼|MU1,019.25+2.66 (+0.26%) ▲|NEE84.09+0.66 (+0.79%) ▲|NFLX76.62-1.63 (-2.09%) ▼|NKE38.17-0.24 (-0.61%) ▼|NOW135.35-5.91 (-4.18%) ▼|NVDA226.66-3.70 (-1.61%) ▼|ORCL164.53+5.75 (+3.62%) ▲|PEP137.98+0.35 (+0.25%) ▲|PFE27.87-0.58 (-2.04%) ▼|PG144.69-1.75 (-1.20%) ▼|PLTR171.34-2.99 (-1.72%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.72-2.61 (-2.41%) ▼|ACN178.68-8.05 (-4.31%) ▼|ADBE257.90-8.61 (-3.23%) ▼|AMAT470.10+15.39 (+3.38%) ▲|AMD508.05+30.48 (+6.38%) ▲|AMGN395.81-41.42 (-9.47%) ▼|AMT177.45+1.60 (+0.91%) ▲|AMZN257.21-1.30 (-0.50%) ▼|AVGO371.22+13.32 (+3.72%) ▲|AXP327.57+1.41 (+0.43%) ▲|BA215.19+2.94 (+1.39%) ▲|BAC62.65-0.04 (-0.06%) ▼|BKNG182.48-10.81 (-5.59%) ▼|BLK1,106.10-10.46 (-0.94%) ▼|BMY65.01-1.81 (-2.71%) ▼|BNY164.30-0.55 (-0.33%) ▼|BRK-B504.34-1.69 (-0.33%) ▼|C137.64-0.09 (-0.06%) ▼|CAT828.40+14.46 (+1.78%) ▲|CL88.20-0.57 (-0.64%) ▼|CMCSA26.15-0.35 (-1.30%) ▼|COF216.29-3.32 (-1.51%) ▼|COP135.48+1.22 (+0.91%) ▲|COST907.74-8.01 (-0.87%) ▼|CRM250.47-8.77 (-3.38%) ▼|CSCO109.38+0.18 (+0.16%) ▲|CVS95.76-0.98 (-1.02%) ▼|CVX211.10+2.50 (+1.20%) ▲|DE683.73-9.80 (-1.41%) ▼|DHR205.78-1.88 (-0.91%) ▼|DIS104.56-0.75 (-0.71%) ▼|DUK121.17+0.95 (+0.79%) ▲|EMR153.67+0.85 (+0.56%) ▲|FDX318.85-3.67 (-1.14%) ▼|GD356.23-3.17 (-0.88%) ▼|GE338.87+1.75 (+0.52%) ▲|GEV961.23+19.28 (+2.05%) ▲|GILD146.16-4.84 (-3.20%) ▼|GM85.74-2.02 (-2.30%) ▼|GOOG335.45+0.14 (+0.04%) ▲|GOOGL338.53+0.07 (+0.02%) ▲|GS1,039.75+1.14 (+0.11%) ▲|HD317.30-3.75 (-1.17%) ▼|HON208.59-1.02 (-0.49%) ▼|IBM232.56-2.33 (-0.99%) ▼|INTC104.17+8.37 (+8.74%) ▲|INTU314.87-17.83 (-5.36%) ▼|ISRG350.35-16.35 (-4.46%) ▼|JNJ267.95-7.28 (-2.65%) ▼|JPM356.50-2.15 (-0.60%) ▼|KO87.91-0.16 (-0.18%) ▼|LIN470.26-7.31 (-1.53%) ▼|LLY1,119.32-30.04 (-2.61%) ▼|LMT540.95+15.67 (+2.98%) ▲|LOW202.44-2.02 (-0.99%) ▼|LRCX321.09+13.44 (+4.37%) ▲|MA568.31-10.91 (-1.88%) ▼|MCD255.65-0.04 (-0.02%) ▼|MDLZ60.97-0.31 (-0.51%) ▼|MDT91.82-2.35 (-2.50%) ▼|META616.72-0.05 (-0.01%) ▼|MMM166.26-2.30 (-1.36%) ▼|MO67.93-0.95 (-1.38%) ▼|MRK148.31-2.02 (-1.34%) ▼|MS218.05+0.33 (+0.15%) ▲|MSFT492.98-6.72 (-1.34%) ▼|MU1,019.25+2.66 (+0.26%) ▲|NEE84.09+0.66 (+0.79%) ▲|NFLX76.62-1.63 (-2.09%) ▼|NKE38.17-0.24 (-0.61%) ▼|NOW135.35-5.91 (-4.18%) ▼|NVDA226.66-3.70 (-1.61%) ▼|ORCL164.53+5.75 (+3.62%) ▲|PEP137.98+0.35 (+0.25%) ▲|PFE27.87-0.58 (-2.04%) ▼|PG144.69-1.75 (-1.20%) ▼|PLTR171.34-2.99 (-1.72%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|
25.3 C
New York
Tuesday, September 8, 2026

Tag: congress

newssourceFORcompanyinformationcontent1releasesmarket

Adhesive Tapes Market worth $111.31 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 17, 2025 /PRNewswire/ -- The report "Adhesive Tapes Market by Resin Type (Acrylic, Rubber, Silicone), Technology (Solvent, Hot-Melt, Water-Based), Backing Material...

Digital Railway Market worth $127.54 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 16, 2025 /PRNewswire/ -- The Digital Railway Market is estimated to be USD 82.76 billion in 2025 and is projected to...

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy.

LNG Station Market worth $1.56 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., June 16, 2025 /PRNewswire/ -- The global LNG Station Market is anticipated to grow from estimated USD 1.02 billion in 2025 to...

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCongress

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers